Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting-Reference-Cited by-同舟云学术

Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting

Published:2024-06-06 Issue:9 Volume:103 Page:3811-3813
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Kikuchi Taku^ORCID,Tsukada Nobuhiro,Kunisada Kodai,Matsumoto Chiaki,Nomura-Yogo Moe,Oda Yuki,Sato Kota,Takei Tomomi,Ogura Mizuki,Abe Yu,Suzuki Kenshi,Hosoya Osamu,Ishida Tadao

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05835-4.pdf

Reference8 articles.

1. Pawlyn C, Cairns D, Kaiser M, Striha A, Jones J, Shah V et al (2020) The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia 34(2):604–612. https://doi.org/10.1038/s41375-019-0595-5

2. D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A et al (2022) Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the Harmony project. J Clin Oncol 40(29):3406–3418. https://doi.org/10.1200/JCO.21.02614

3. Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B et al (2020) Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol 6(11):1759–1765. https://doi.org/10.1001/jamaoncol.2020.4338

4. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

5. Iriuchishima H, Saito A, Mihara M, Terasaki Y, Matsumoto A, Isoda A et al (2024) Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain. Int J Hematol. https://doi.org/10.1007/s12185-024-03760-w